Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202607082 The use of Osteo-Inductive-Factor/β-Tri-Calcium Phosphate (OIF/β-TCP) for the Alveolar Ridge Preservation. New Medical Device NA
N202607098 A Randomized, Open-label, Phase 3 Trial of Petosemtamab in Combination With mFOLFOX6 or FOLFIRI Versus Cetuximab in Combination With mFOLFOX6 or FOLFIRI as First-line Treatment for Participants With RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer New Drug Phase Ⅲ
N202607099 An Open-Label, Single Arm, Phase 2a Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Mild-to-Moderate Alopecia Areata New Drug Phase Ⅱ
N202607102 Development and Validation of Transcutaneous Vagus Nerve Stimulation Therapeutics Medical Device for Symptoms of Anxiety among Psychiatric Outpatients New Medical Device NA
N202608003 Clinical Validation of the ArteVu Research Configuration for Cuff-less Blood Pressure Estimation using an Oscillometric Reference New Medical Device NA
N202608004 A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI INCLINE) New Drug Phase Ⅲ
N202608005 A Phase II Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of AR100DP1 in Subjects with Mild to Moderate Atopic Dermatitis New Drug Phase Ⅱ
N202608010 A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF TRONTINEMAB IN COGNITIVELY UNIMPAIRED INDIVIDUALS AT RISK FOR PROGRESSION TO SYMPTOMATIC ALZHEIMER’S DISEASE New Drug Phase Ⅲ
N202608016 A Phase 1b/2a, Multicenter, Open-Label Study of Pidnarulex (CX-5461) in Combination with Tislelizumab in Patients with Advanced or Metastatic Solid Tumors New Drug Phase Ⅰ
N202608017 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 In Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) New Drug Phase Ⅱ
1 2 23 24 25 26 27 28 29 30 31 32 / 32

TOP